Neurocrine Biosciences CMO reports 51,331 shares

Neurocrine Biosciences (NBIX) began a Phase 2 trial for NBI-1117567, an Alzheimer’s drug candidate. The study will evaluate 135 adults with mild to moderate Alzheimer’s over 12 weeks. Primary efficacy is measured by changes in a Neuropsychological Test Battery composite score. Neurocrine aims to develop new treatments for Alzheimer’s disease.

Neurocrine Biosciences (NBIX) presented real-world data on congenital adrenal hyperplasia, showing varied and evolving impacts across patients' lifespans. The data highlighted diverse clinical needs and persistent treatment demands. The company suggests this could aid healthcare professionals in providing better support.

Needham reiterated a Buy rating on Neurocrine Biosciences with a $204 price target, suggesting a 49% upside from the latest close. The company's strong portfolio of FDA-approved treatments and promising pipeline were highlighted as key strengths.

Patient advocates and experts raise concerns over safety issues with Neurocrine Biosciences' drug Vykat XR, approved for Prader-Willi syndrome. The drug has been linked to seven deaths and nearly 100 hospitalizations since its approval 18 months ago, though regulators note no proven causality. Some experts believe the evidence shows unacceptable harm.

Neurocrine Biosciences, Inc. announced Eiry W. Roberts, M.D., will return as Chief Medical Officer, effective September 28, 2026. Dr. Sanjay Keswani's tenure as CMO ended on September 25, 2026. Dr. Roberts previously led key drug development programs at Neurocrine.

Neurocrine Biosciences (NBIX) reported positive Phase 4 study results for INGREZZA, showing significant patient improvement in tardive dyskinesia. The company also reported Q2 revenue growth of 39% to $959M, with INGREZZA sales up 15%. Neurocrine acquired Soleno Therapeutics, reducing cash reserves but expanding its drug portfolio. The stock trades at a forward P/E of 14.88.